FT in prognostic of HBV FibroTest: predictive value in HBV

FT in prognostic of HCV 1. Diagnosis and clinical options 2. FibroTest: a 4-years prognostic study In this Presentation

FT in prognostic of HBV Diagnosis and clinical options

FT in prognostic of HCV 95% 5% (For liver injuries Assessment) Diagnosis and clinical options Positive serology Poynard et al, Comp Hepatol 2004

FT in prognostic of HBV 5 years prognostic value FibroTest

FT in prognostic of HCV Ngo et al, Hepatology AASLD Patients and Methods Aim  To prospectively assess the 4-year prognostic value of FibroTest-ActiTest staging compared to biopsy and to HBV-DNA for predicting cirrhosis decompensation and survival. Patients and method  Prospective hospital-based cohort of chronic hepatitis B patients (n=504) (consecutive Ag HBs positive patients with baseline FibroTest-ActiTest HBV DNA measurements)  Mean age 42 yrs,71% males,  30% asian  AgHBe+ 18%  HBV-related complications (main end-point):  liver-related death  liver transplantation  liver failure (ascites, jaundice, hepatic encephalopathy)  variceal bleeding,  hepatocellular carcinoma

FT in prognostic of HCV Ngo et al, Hepatology AASLD Results 4-year survival without HBV related complications according for FibroTest severity groups -- Minimal fibrosis -- Moderate fibrosis -- severe fibrosis Survival without complications months Baseline FT value n HBV complications Survival without HBV complications ( ) ( ) ( ) All ( )

FT in prognostic of HCV 4-year survival without HBV related death according for FibroTest severity groups -- Minimal fibrosis -- Moderate fibrosis -- severe fibrosis Survival without complications months Baseline FT value n HBV related death Survival without HBV complications ( ) All ( ) Ngo et al, Hepatology AASLD Results

FT in prognostic of HCV Better AUROCs for FibroTest versus HBV-DNA for 4-years survival without HBV complications or death AUROC: 4 years without complications FT AUROC (95%CI) HBV-DNA AUROC (95%CI) p 0.89 ( )0.57 ( )<0.001 AUROC: 4 years without death FT AUROC (95%CI) HBV-DNA AUROC (95%CI) p 0.95 ( )0.55 ( )<0.001 Ngo et al, Hepatology AASLD Results Sensivity Specificity -- FibroTest -- HBV DNA Sensivity Specificity -- FibroTest -- HBV DNA

FT in prognostic of HCV Similar AUROCs for FibroTest and Biopsy of 4-year survival without HBV complications and death FT AUROC (95%CI) Liver biopsy AUROC (95%CI) p 0.99 ( )0.97 ( )0.32 Ngo et al, Hepatology AASLD Results

FT in prognostic of HCV Ngo et al, Hepatology AASLD 2007 Conclusions FibroTest’s prognostic valuePossible combinations of FT 4-year prognostic value  similar to that of liver biopsy  better to that of HBV-DNA  With baseline viral load  To improve prediction for  Death  Complications

FT in prognostic of HBV